Drik is a preclinical contract research organization ( CRO ) specializing in preclinical drug development. Drik preclinical testing services support an expanding range of in vitro testing and animal studies for preclinical drug discovery, cosmetic and chemical industries. Drik provides in vivo testing and toxicology tests in its laboratories including cell based assays and cell assays exploring the causes of diseases and the potential safety concerns. We evaluate toxicity of new agents using biological systems including animal models. Drik's premium niche service is in 3D Organotypic slice cultures, a leading industry initiative in providing reliable de-risk strategy.
DRIK has the capability in house performing different standard assays to measure biochemical processes that are important for cell health. Each assay is performed using a range of exposure concentrations (1-300 µM). We also provide customized assay based on client needs.Efficacy and Safety
These data will provides an estimated blood concentration where toxicity would be expected to occur and results will be compared with standard toxicant.
Rapid turnaround time
Minimal compound requirement, typically 8 mg or less to perform all assays.
We will provide a detailed interpretive report with comparative analysis of toxicity and order ranking of potential lead candidates based on efficacy and toxicity.
Few End Points Often Studied:
Apoptosis (Casp3/7/8/9), BrDU
Cell signaling and communication
Viability and cytotoxicity
Invasion and motility
Integrated In Vitro-In Vivo Studies:
Cancer research (Xenograft studies)
CYP inhibition/Induction(CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4)
Drug-Drug Interaction(DDI) studies
Pathway determination(Phase I and Phase II)
Half-life/clearance determination using Microsomes / Hepatocytes / S9 fractions / CYP across species (Human/Rat/Mouse/Dog)
Metabolite identification with Microsomes/Hepatocytes and S9 fraction across species (Rat/Mouse/Dog/Human)
We are proud to introduce the in vitro 3D Organotypic slice culture model for determination of toxicity of compounds. The advantages of the model is that -
presence of all cell types without any disturbance of natural milieu;
duration-dose dependent changes can be studied (ability to study changes for 14 days or more; not possible with cell lines);
ability to track the cellular changes in real time and
derive a dose-response curve
Cancer models (Xenograft and Orthotopic)
Short term and long term toxicity studies
MTD and DRF studies
Sub-acute and chronic toxicity studies
Blood chemistry, Clinical Pathology
Drug induced Liver and Kidney toxicity
Liver Injury Markers: ALT, AST, GLDH, PNP, ARG-1, GST-a,mir-122
Clinical Liver Injury Markers: GLDH, MDH, GST-a, ARG-1, miR-122, ALP, 5'-NT, GGT, LDH
Nephrotoxicity: ß2-microtubulin, KIM-1, TFF-3, Serum Cystatin C, RBP-4, GST-a, NAG, NGAL